FDA Announces Public Meeting to Discuss Abuse-Deterrent Properties of Opioid Drug Products

Summary

The Food and Drug Administration (FDA) is hosting a public meeting to gather input from various stakeholders on its approach to evaluating the abuse-deterrent properties of opioid drug products, as outlined in its draft guidance, and to discuss the development of standardized testing methodologies for these products.